Top 5 Stocks to Buy Now
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:HCM

HUTCHMED 6/18/2026 Earnings Report

HUTCHMED logo
$10.16 +0.17 (+1.70%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

HUTCHMED EPS Results

Actual EPS
N/A
Consensus EPS
-$0.36
Beat/Miss
N/A
One Year Ago EPS
N/A

HUTCHMED Revenue Results

Actual Revenue
N/A
Expected Revenue
$80.92 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HUTCHMED Announcement Details

Quarter
Date
6/18/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

HUTCHMED Earnings Headlines

Syndio Acquires Embrace.ai
June 23 at 12:30 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260623406678/en/syndio-acquires-embrace.ai/
isolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors Directory
June 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312891/0/en/isolved-Introduces-Autonomous-AI-Agents-Built-to-Own-HR-Outcomes-Brings-Unified-HCM-Platform-to-Anthropic-s-Claude-Connectors-Directory.html
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
June 23 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-positive-top-line-data-from-12-week-phase-2-cirrus-hcm-trial-with-edg-7500-in-obstructive-and-nonobstructive-hypertrophic-cardiomyopathy-hcm-302801108.html
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312225/0/en/isolved-honors-top-performing-partners-at-annual-connect-for-partners-event.html
isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311996/0/en/isolved-introduces-new-strategic-marketplace-partners-at-connect-2026-extending-people-cloud-capabilities-for-employers-and-employees.html
See More HUTCHMED Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HUTCHMED? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HUTCHMED and other key companies, straight to your email.

About HUTCHMED

HUTCHMED (NASDAQ:HCM) (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets.

Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.

View HUTCHMED Profile
Earnings Tools